Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LGX818 plus MEK162 versus vemurafenib or LGX818 monotherapy in BRAF V600-mutant advanced melanoma
NL-OMON53071Phase 3Active, not recruiting
- Sponsor
- Array BioPharma
- Start
- Jan 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of encorafenib, binimetinib and vemurafenib in melanoma (4 arms), sponsored by Array BioPharma. Primary endpoint: Progression-free survival. Started Jan 2014; status: active, not recruiting.
02
Drugs
encorafenibbinimetinibvemurafenib
03
Conditions
melanoma
Beyond the preview
Go deeper on NL-OMON53071.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53071.